Midatech Pharma - MTX110 receives ODD from the EMA for gliomas
Midatech’s lead clinical asset, MTX110, has achieved another regulatory milestone following the decision by the European Medicines Agency (EMA) to grant the drug orphan drug designation for the treatment of gliomas. This includes recurrent glioblastoma (rGBM), diffuse intrinsic pontine glioma (DIPG) and medulloblastoma, currently being targeted by MTX110. ODD should grant Midatech 10 years of market exclusivity on approval, in addition to other incentives such as protocol development assistance and reduced fees. As a reminder, MTX110 already has ODD in DIPG and recently received fast track designation for rGBM by the US FDA.Midatech Pharma is a holding company. Through its subsidiaries, Co. is engaged as a specialty pharmaceutical company focused on the development and commercialization of multiple therapeutic products, using its nanomedicine and sustained release technologies, to enhance the delivery of medicines in major diseases with high unmet medical needs. These diseases include diabetes, certain cancers such as liver, ovarian and brain (glioblastoma) and neurological/ophthalmologic conditions. Co.'s two platform technologies are designed to enable targeted delivery and sustained release of existing therapeutic drugs to the "right place" at the "right time."
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.